Mark J. Ratain to In Situ Hybridization, Fluorescence
This is a "connection" page, showing publications Mark J. Ratain has written about In Situ Hybridization, Fluorescence.
Connection Strength
0.073
-
A phase I trial of escalating doses of trastuzumab combined with daily subcutaneous interleukin 2: report of cancer and leukemia group B 9661. Clin Cancer Res. 2002 Dec; 8(12):3718-27.
Score: 0.051
-
Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med. 2010 Oct 28; 363(18):1693-703.
Score: 0.022